AiCure has picked up series C capital from investors such as Singtel Innov8 and Asahi Kasei to bolster its commercial, engineering and R&D efforts.
Singtel Innov8, the corporate venturing arm of telecommunications firm Singtel, and chemicals producer Asahi Kasei yesterday backed a $24.5m series C round for US-based digital health technology provider AiCure.
Palisades Growth Capital led the round, which included Accelmed Growth Partners and SpringRock Ventures, as well as Baird Capital, New Leaf Venture Partners, Pritzker Group, Biomatics Capital, Tribeca Venture Partners and Silicon Valley Bank.
Founded in 2010, AiCure has developed artificial intelligence technology that assesses how patients respond to treatments in…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
